These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 24382349)

  • 1. Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.
    Kagoya Y; Yoshimi A; Kataoka K; Nakagawa M; Kumano K; Arai S; Kobayashi H; Saito T; Iwakura Y; Kurokawa M
    J Clin Invest; 2014 Feb; 124(2):528-42. PubMed ID: 24382349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [NF-κB activity in myeloid leukemia stem cells].
    Kagoya Y
    Rinsho Ketsueki; 2015 Apr; 56(4):384-91. PubMed ID: 25971268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML.
    Volk A; Li J; Xin J; You D; Zhang J; Liu X; Xiao Y; Breslin P; Li Z; Wei W; Schmidt R; Li X; Zhang Z; Kuo PC; Nand S; Zhang J; Chen J; Zhang J
    J Exp Med; 2014 Jun; 211(6):1093-108. PubMed ID: 24842373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
    Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
    Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling.
    Li J; Volk A; Zhang J; Cannova J; Dai S; Hao C; Hu C; Sun J; Xu Y; Wei W; Breslin P; Nand S; Chen J; Kini A; Zhu J; Zhang J
    Oncotarget; 2017 Jan; 8(5):8420-8435. PubMed ID: 28039479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-32θ gene expression in acute myeloid leukemia suppresses TNF-α production.
    Kim MS; Kang JW; Jeon JS; Kim JK; Kim JW; Hong J; Yoon DY
    Oncotarget; 2015 Dec; 6(38):40747-61. PubMed ID: 26516703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors.
    Nakagawa M; Shimabe M; Watanabe-Okochi N; Arai S; Yoshimi A; Shinohara A; Nishimoto N; Kataoka K; Sato T; Kumano K; Nannya Y; Ichikawa M; Imai Y; Kurokawa M
    Blood; 2011 Dec; 118(25):6626-37. PubMed ID: 22021368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.
    Jin Y; Lu Z; Ding K; Li J; Du X; Chen C; Sun X; Wu Y; Zhou J; Pan J
    Cancer Res; 2010 Mar; 70(6):2516-27. PubMed ID: 20215516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Grosjean-Raillard J; Tailler M; Adès L; Perfettini JL; Fabre C; Braun T; De Botton S; Fenaux P; Kroemer G
    Oncogene; 2009 Feb; 28(8):1099-109. PubMed ID: 19079347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-33-dependent NF-κB activation inhibits apoptosis and drives chemoresistance in acute myeloid leukemia.
    Yan M; Chen X; Ye Q; Li H; Zhang L; Wang Y
    Cytokine; 2024 Aug; 180():156672. PubMed ID: 38852492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target.
    Zhou J; Ching YQ; Chng WJ
    Oncotarget; 2015 Mar; 6(8):5490-500. PubMed ID: 25823927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
    Dai Y; Chen S; Wang L; Pei XY; Kramer LB; Dent P; Grant S
    Br J Haematol; 2011 Apr; 153(2):222-35. PubMed ID: 21375523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells.
    Takada Y; Andreeff M; Aggarwal BB
    Blood; 2005 Jul; 106(2):641-9. PubMed ID: 15811958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
    Dai Y; Rahmani M; Grant S
    Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
    Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of NF-κB signaling pathway in HSV-1-induced mouse facial palsy: Possible relation to therapeutic effect of glucocorticoids.
    Liu W; Fan Z; Han Y; Xu L; Wang M; Zhang D; Mao Y; Li J; Wang H
    Neuroscience; 2015 Mar; 289():251-61. PubMed ID: 25595974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
    Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
    Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
    Ma MH; Yang HH; Parker K; Manyak S; Friedman JM; Altamirano C; Wu ZQ; Borad MJ; Frantzen M; Roussos E; Neeser J; Mikail A; Adams J; Sjak-Shie N; Vescio RA; Berenson JR
    Clin Cancer Res; 2003 Mar; 9(3):1136-44. PubMed ID: 12631619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TAK1-NF-κB axis as therapeutic target for AML.
    Bosman MC; Schepers H; Jaques J; Brouwers-Vos AZ; Quax WJ; Schuringa JJ; Vellenga E
    Blood; 2014 Nov; 124(20):3130-40. PubMed ID: 25287709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosmarinic acid sensitizes cell death through suppression of TNF-alpha-induced NF-kappaB activation and ROS generation in human leukemia U937 cells.
    Moon DO; Kim MO; Lee JD; Choi YH; Kim GY
    Cancer Lett; 2010 Feb; 288(2):183-91. PubMed ID: 19619938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.